TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01091285

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Description: Foley Catheter 16-19 H

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double Balloon Catheter
Description: Double Balloon Catheter for 16-19H
Study: NCT00831246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chewing gum - Extra Winterfresh
Description: Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Post-Op Care
Description: Patients are given standard post-op care with clear liquid diet as tolerated.
Study: NCT02970747

Intervention type: DRUG
Intervention: Carfilzomib
Description: In accordance with SmPC.

Intervention type: DRUG
Intervention: Carfilzomib
Description: In accordance with SmPC.

Intervention type: DRUG
Intervention: Carfilzomib
Description: In accordance with SmPC.
Study: NCT02407509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766
Study: NCT03894904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: 2 units/mL heparin administered as soon as the arterial catheter is placed and secured, and 2 units/mL heparin administered one hour after initial dose
Study: NCT02000258

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Double-bundle ACL reconstruction

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic resonance imaging (MRI)
Description: MRI sequences were as follows: sagittal T1-weighted, proton density (PD)-weighted and T2-weighted fast spin echo (FSE) images with 4 mm slice and 1 mm gap, coronal T1-weighted and fat-saturated T2-weighted FSE images with 4 mm slice and 1 mm gap, axial fat saturated PD FSE images with 4 mm slice and 1 mm gap and oblique sagittal and oblique coronal T1 FSE images along AM graft plane with 3 mm slice and 0.3 mm gap.
Study: NCT02711345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTT462
Description: ERK Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTT462
Description: ERK Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTT462
Description: ERK Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTT462
Description: ERK Inhibitor
Study: NCT02815774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP2086
Description: all subjects were given SP2086 50mg only one time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP2086
Description: all subjects were given SP2086 50mg only one time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP2086
Description: all subjects were given SP2086 50mg only one time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP2086
Description: all subjects were given SP2086 50mg only one time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP2086
Description: all subjects were given SP2086 50mg only one time.
Study: NCT00973570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TABADO program
Description: The intervention takes place in 3 stages: (i) a general information session on tobacco consumption is delivered to all teenagers, both smokers and nonsmokers. (ii) For smokers wishing to join the program, this session is followed by individualized consultations with a team of tobacco addiction physicians. (iii) The volunteers then benefit from a small group approach, consisting of discussion sessions to share experiences, strengthen motivation, and prevent relapse. There will be 4 sessions in total, comprising individual counseling and work in groups spread over 3 months (taking into account the availability of the trainees because of their alternate-week training schedule).
Study: NCT03347708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDCT
Description: Discogenic Cells + Sodium Hyaluronate Vehicle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDCT
Description: Discogenic Cells + Sodium Hyaluronate Vehicle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Sodium Chloride Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium Hyaluronate Vehicle
Study: NCT03901898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training, audit, and reminders
Description: Briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter), and re-audit at 6 months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention after 6 months (wait list)
Description: After 6 months, practices receive the intervention: briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter).
Study: NCT02571036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2618
Description: 50 mg formulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2618
Description: 50 mg formulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2618
Description: 50 mg formulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2618
Description: 50 mg formulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2618
Description: 50 mg formulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2618
Description: 50 mg formulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2618
Description: 50 mg formulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2618
Description: 50 mg formulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2618
Description: 50 mg formulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2618
Description: 50 mg formulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2618
Description: 50 mg formulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2618
Description: 10 mg and 50 mg formulated tablets
Study: NCT02352233

Intervention type: PROCEDURE
Intervention: RETROVIEW colonoscope
Description: withdrawal in retro vision and forward vision was performed by segments (right, transverse, left, sigmoid colon and rectum). Retroflexed therapeutics procedures were executed when needed.
Study: NCT03766360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Analytical Psychotherapy (FAP)
Description: The intervention itself is based on the procedures of Functional Analytic Psychotherapy, a behavioral intervention focusing on improving social functioning.
Study: NCT01625403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBNP
Description: intravenous administration of rhBNP 0.01 µg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: standard of care for heart failure
Study: NCT01344018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study: NCT03655860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMEOX
Description: SIMEOX is a device generating a succession of gentle depression at the mouth.
Study: NCT02321839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraviteal Ranibizumab 0.5mg
Description: Intraviteal Ranibizumab 0.5mg
Study: NCT03989141

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repeated cannulation Buttonhole.
Description: The intervention group (I): repeated needling into the same site in the AVF with sharp needles (4-6 pieces) at each dialysis (1-3 dialyses) creating a buttonhole tunnel track where cannulation with a blunt needle is possible.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single cannulation Buttonhole.
Description: The control group (C): needling into the same site in the AVF with 1 sharp needle at each dialysis (6-12 dialyses) creating a buttonhole tunnel track, where cannulation with a blunt needle is possible. .
Study: NCT01622764

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Molecular imaging with 89Zr-RO5323441
Description: Bevacizumab at a dose of 10 mg/kg body weight i.v. in 90 min on day 1 will be given every 2 weeks in cycles of 6 weeks, until documented disease progression, unacceptable toxicity, patient refusal or patient's best interest. 89Zr-RO5323441 will be administered i.v. at a tracer dose of 5 mg (37 MBq) on day -3 and on day 11 of cycle 1 of bevacizumab treatment. Four PET scans will be performed (2 brain only PET scans and 2 whole body PET scans). Brain only PET scans will be performed 2 hours after each 89Zr-RO5323441 administration on day -3 and day 11. Whole body PET scans will be performed 4 days after each 89Zr-RO5323441 administration (before dosing with bevacizumab on day 1 and day 15).
Study: NCT02581527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)
Study: NCT00739596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks
Description: Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine: 8 weeks
Description: Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks
Study: NCT03813823

Intervention type: BEHAVIORAL
Intervention: Fear tasks
Description: All participants will be exposed to 5 fear tasks involving spiders, with increasing fear intensity.
Study: NCT03894904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue papaverine, as needed
Description: If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second papaverine plus heparin or heparin only dose, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue papaverine, as needed
Description: If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second papaverine plus heparin or heparin only dose, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
Study: NCT03080922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell
Description: high dose of donor G-CSF mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
Study: NCT02349477

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a pill that looks exactly like the active medication but does not contain medication
Study: NCT02241772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03484195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: Irinotecan 150 mg/m\^2 IV over 1h, day 1 + Oxaliplatin 85 mg/m\^2 IV over 2h, day 1 + L-Leucovorin 200 mg/m\^2 IV over 2h, day 1 + 5-Fluorouracil 2800 mg/m\^2 IV 48h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months)
Study: NCT01866735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Rehabilitation Therapy
Study: NCT02527083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study: NCT02581527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)
Study: NCT02527083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Study: NCT03584386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-CAMS (aka Jaspr)
Description: V-CAMS is an integrated software system for use on any device by suicidal patients.
Study: NCT02813512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADSCs
Description: Autologous ADSCs
Study: NCT02844712

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of reexposure to a negatively tested betalactam
Study: NCT00987935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: Twice daily
Study: NCT00667979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 10mg and 20mg to be taken 12, 18, 24 hours prior to sexual intercourse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03352180

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic reapir of subscapularis tendon
Description: arthroscopic reapir of massive rotator cuff tears involving the subscapularis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic debridement of subscapularis tendon
Description: arthroscopic debridement of massive rotator cuff tears involving the subscapularis.
Study: NCT01326897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Homes/Healthy Families
Description: Participants in the intervention group will work with coaches to make their homes more supportive of healthy eating and physical activity. Each intervention participant will receive a tailored home environment profile, and will select from a menu of healthy actions to make changes in their home. The intervention will be delivered over the course of 5 months, with 3 home visits, 4 coaching calls, and 4 support mailings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Study participants in this group will receive health education materials by mail (3 times over the course of 5 months).
Study: NCT03981198

Intervention type: DEVICE
Group type: OTHER
Intervention: Soliton Rapid Acoustic Pulse (RAP)
Description: Treatment of legs and/or buttocks for the temporary improvement in the appearance of cellulite.
Study: NCT03931512

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimularion
Description: aplication of direct current stimulation on the scalp wiht sponge electrodes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimularion
Description: aplication of direct current stimulation on the scalp wiht sponge electrodes
Study: NCT03795870

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polymeric Tube Feeds
Description: Polymeric tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with blenderized tube feeds

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blenderized Tube Feeds
Description: Blenderized tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with polymeric tube feeds
Study: NCT02349828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Study: NCT00007774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Study: NCT00345592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual (atrial and ventricular) implantable defibrillator
Description: The devices automatically applies therapy (shock) for atrial fibrillation, when atrial fibrillation is confirmed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual (atrial and ventricular) implantable defibrillator
Description: In hospital application of anti arrhythmic therapies via the device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual (atrial and ventricular) implantable defibrillator
Description: Therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment
Study: NCT00551993

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic laparoscopic sacrocolpopexy
Description: Da Vinci Robot

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Sacral Colpopexy
Description: Standard laparoscopy
Study: NCT02275533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo standard of care clinical observation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04305652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Progressively Lowered Stress Threshold Model
Description: PLST is a conceptual model for reducing behavioral symptoms in individuals with dementia. The PLST model provides the foundation for a psychoeducational intervention that assists formal and informal caregivers in understanding behaviors and planning care for individuals with dementia. If the model is to be applied at home, at least three home visits are made in line with the listed principles. While making a diagnosis during the first home visit, a maintenance plan for the problems is created in other home visits and the caregiver is trained to implement the care plan. After the home visits, the process is carried out by providing counseling through telephone calls or face-to-face interviews when necessary.
Study: NCT01284738

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiopathology
Description: Three sequential biological evaluations will be performed for each patient and will consist in :~* the dosages of MP carried out by the UMR 608 in Marseille,~* the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat.~In vitro production of MP of transfused red blood cells origin will also be evaluated in erythrocytes concentrates during the storage of the units.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiopathology
Description: Three sequential biological evaluations will be performed for each patient and will consist in :~* the dosages of MP carried out by the UMR 608 in Marseille,~* the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat.
Study: NCT02581527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid 75mg - all arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid 75mg - all arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid 75mg - all arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Ethambutol 275mg - all arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Ethambutol 275mg - all arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Ethambutol 275mg - all arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide 400mg - all arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: Pyrazinamide 400mg - all arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide 400mg - all arms
Study: NCT04508205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGB-400
Description: BID application
Study: NCT03062410

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic PRO in daily clinical practice
Description: All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
Study: NCT06298162

Intervention type: OTHER
Intervention: 2 years after RYGB, no intervention. MRI measurement. Observational.
Description: no intervention. MRI measurement. Observation.

Intervention type: OTHER
Intervention: 2 years after RYGB, no intervention. MRI measurement. Observational.
Description: no intervention. MRI measurement. Observation.
Study: NCT03845049

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inclusion examinations
Description: Pregnancy test, Visual acuity, ocular pressure, color retinophotography, OCT-SD (the Heidelberg SDOCT Spectralis, or the Cirrus HD-OCT, model 5000, Zeiss), OCT-angiography and fluorescein angiography and wide-field angiogram

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclusion examinations
Description: Pregnancy test, Visual acuity, ocular pressure, color retinophotography, OCT-SD (the Heidelberg SDOCT Spectralis, or the Cirrus HD-OCT, model 5000, Zeiss), OCT-angiography and fluorescein angiography and wide-field angiogram
Study: NCT03051776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression Garment
Study: NCT00458822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally